

**Proteome Sciences plc**  
**(“Proteome Sciences” or the “Company”)**

**Issue of Equity**

Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) as payment for professional services.

Application has been made to the London Stock Exchange for the 533,333 new Ordinary Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 7 September 2017.

After Admission, the total number of Ordinary Shares in issue will be 295,182,056 and the total number of voting rights will therefore be 295,182,056. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

**For further information:**

**Proteome Sciences plc**

Jeremy Haigh, Chief Executive Officer  
Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

**finnCap Limited (Nominated Adviser & Broker)**

Geoff Nash/James Thompson  
Tony Quirke (Broking)

Tel: +44 (0)20 7220 0500

**IFC Advisory (Financial PR and IR)**

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

**About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer’s disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.